塞克硝唑(Secnidazole) - 在研适应症：贾第虫病，滴虫感染，细菌性阴道炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2 ol、1-(2 hydroxypropyl)-2-methyl-5-nitroimidazole、Secnidazole (USAN/INN)

+ [15]

靶点-

作用机制

DNA合成抑制剂

治疗领域

感染消化系统疾病泌尿生殖系统疾病

在研适应症

贾第虫病滴虫感染细菌性阴道炎

非在研适应症-

原研机构

Sanofi

在研机构

Lupin, Inc.

Ethypharm SAS

非在研机构-

最高研发阶段批准上市

首次获批日期

瑞士 (1980-01-01),

细菌性阴道炎

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)

登录后查看首次获批时间轴

结构

分子式C7H11N3O3

InChIKeyKPQZUUQMTUIKBP-UHFFFAOYSA-N

CAS号3366-95-8

关联

12

项与塞克硝唑相关的临床试验

NCT06261840 / Not yet recruiting临床4期IIT

Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

开始日期2024-07-01

申办/合作机构

Tulane University Hospital & Clinic

[+2]

CTRI/2022/01/039430 / Recruiting临床3期IIT

Triple Arm Randomised Controlled Trial Comparing Metronidazole, Tinidazole And Secnidazole For The Efficacy In The Patients Of Amoebic Liver Abscess (TARMENTS TRIAL) - TARMENTS Trial

开始日期2022-01-31

申办/合作机构-

NCT03935217 / Completed临床3期

Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis

This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.

开始日期2019-04-23

申办/合作机构

Lupin Research, Inc.

100 项与塞克硝唑相关的临床结果

登录后查看更多信息

100 项与塞克硝唑相关的转化医学

登录后查看更多信息

100 项与塞克硝唑相关的专利（医药）

登录后查看更多信息

211

项与塞克硝唑相关的文献（医药）

2024-01-11·Journal of medicinal chemistry1区 · 医学

Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile

1区 · 医学

Article

作者: Ku, Therese C ; Friedman, Jacob ; Newman, Amy Hauck ; Lam, Jenny ; Loland, Claus J ; Shi, Lei ; Camacho-Hernandez, Gisela Andrea ; Klein, Benjamin ; Rais, Rana ; Paule, James ; Won, Sung Joon ; Okorom, Amarachi V ; Xi, Zheng-Xiong ; Cao, Jianjing ; Lee, Kuo Hao ; Salomon, Kristine

Atypical dopamine transporter (DAT) inhibitors have shown therapeutic potential in the preclinical models of psychostimulant use disorders (PSUD). In rats, 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-piperazin-1-yl)-propan-2-ol (JJC8-091, 3b) was effective in reducing the reinforcing effects of both cocaine and methamphetamine but did not exhibit psychostimulant behaviors itself. Improvements in DAT affinity and metabolic stability were desirable for discovering pipeline drug candidates. Thus, a series of 1-(4-(2-bis(4-fluorophenyl)methyl)sulfinyl)alkyl alicyclic amines were synthesized and evaluated for binding affinities at DAT and the serotonin transporter (SERT). Replacement of the piperazine with either a homopiperazine or a piperidine ring system was well tolerated at DAT (K_i range = 3-382 nM). However, only the piperidine analogues (20a-d) showed improved metabolic stability in rat liver microsomes as compared to the previously reported analogues. Compounds 12b and 20a appeared to retain an atypical DAT inhibitor profile, based on negligible locomotor activity in mice and molecular modeling that predicts binding to an inward-facing conformation of DAT.

2024-01-01·Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Selective and sensitive colorimetric detection of endocrine disrupter fungicide carbendazim through secnidazole capped silver nanoparticles

Article

作者: Khan, Muhammad Ali ; Arain, Munazza ; Nafady, Ayman ; Hussain, Saghir ; Ahmad, Hafiz Badaruddin ; Asif, Hafiz Muhammad ; Sirajuddin ; Ul Haq, Muhammad Anwar

Pesticides and fungicides are extremely useful to hinder the attacks of pests and fungi to secure crops, vegetables, fruits and other plants but due to their endocrine disrupting and carcinogenic risks in humans and animals through their continued addition in water resources they are extremely important to monitor carefully. In this investigation we synthesized silver nanoparticles (AgNPs) via the reducing action of sodium borohydride in the presence of secnidazole (SEC) as capping agent under various optimized parameters such as the concentration of NaBH₄, silver nitrate (AgNO₃), SEC and pH. These SEC-AgNPs were characterized through various techniques including ultra-violet visible (UV-Vis) spectroscopy, Fourier transform infra-red (FTIR) spectroscopy, field emission scanning electron microscopy (FESEM), atomic force microscopy (AFM), dynamic light scattering (DLS) and zeta-potential analysis (ZPA) in order to investigate their diverse properties. As prepared SEC-AgNPs were proved as extremely sensitive for trace level sensing of fungicide carbendazim (CARB) in the range of 0.5-22 µM with limit of detection (LOD) equal to 0.021 µM and R² value of 0.9964. SEC-AgNPs were tested for CARB sensing under the presence of several pesticides with negligible interference thus verifying its exclusive selectivity for the targeted analyte. This SEC-AgNPs was further applied to find out the concentration of CARB in real samples of tap water and human blood plasma with reference to standard addition method.

2024-01-01·European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Evaluation of the impact of tragacanth/xanthan gum interpolymer complexation with chitosan on pharmaceutical performance of gels with secnidazole as potential periodontal treatment

Article

作者: Wróblewska, Magdalena ; Potaś, Joanna ; Winnicka, Katarzyna ; Wach, Radosław A ; Rokita, Bożena

Periodontitis consists a group of dental disorders that affect about 70 % of the world population. The therapy mainly relies on mechanical removing bacterial biofilm, nevertheless, local or systemic antibacterial agents play a key role in treating the acute conditions. Secnidazole is a newer derivative of commonly used metronidazole with high safety profile and broad spectrum of antimicrobial activity. The aim of the study was to evaluate the applicability of polyelectrolyte complex-based hydrogels composed of anionic tragacanth with addition of xanthan gum and cationic chitosan as carriers for buccal/intra pocket delivery of secnidazole. Prepared hydrogels with 5 % and 10 % (w/w) drug content were evaluated pharmaceutically towards inter alia physicomechanical, rheological and thermal properties, drug release kinetics, swelling behavior or antimicrobial activity. Cytotoxicity against human primary umbilical vein endothelial cells was also assessed with two independent method. Stable compositions with secnidazole were obtained, however, various miscibility of the drug with the polymers was noted. By adding chitosan, antibacterial activity and swelling performance of the gels were improved, nevertheless, drop of the mucoadhesiveness was also recorded. Hydrogels with 5 % secnidazole were selected as effective antimicrobial compositions with the highest cytocompatibility. They might be considered as promising for oromucosal application with special attention given to SEC as an alternative locally administered antimicrobial agent.

7

项与塞克硝唑相关的新闻（医药）

2024-03-08

·药融圈

投资5.68亿！尚科生物子公司苏泊尔制药高端原料药绿色合成产业化建设项目

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。近日，关于浙江苏泊尔制药有限公司高端原料药绿色合成产业化建设项目在相关网站公示。项目基本情况项目名称：苏泊尔制药高端原料药绿色合成产业化建设项目建设性质：迁建建设地点：杭州湾上虞经济技术开发区投资：总投资56819.98万元，其中环保投资7590万元，占总投资比例的13.36%。项目组成：项目新征用地101亩，新建车间、仓库、控制楼、消防泵房等建（构）筑物，购置反应釜等设备，实施袍江厂区原料药生产线搬迁，形成年产612吨原料药（包括替硝唑、奥硝唑、塞克硝唑、硫酸羟氯喹、普瑞巴林等18种）、20吨中间体（包括依鲁替尼中间体和拉莫三嗪中间体2种）的生产能力，并利用产出的中间品回收生产硫酸铵、聚合氯化铝、溴化钠、乙腈和乙醇副产品。在本项目实际排污前，现有袍江厂区原料药生产线进行淘汰替代，制剂生产线不搬迁保留在袍江厂区内继续生产。袍江厂区现涉及替硝唑、奥硝唑、塞克硝唑、盐酸安非他酮、非洛地平、拉莫三嗪、富马酸喹硫平和舒马曲坦共8种原料药产品的生产，本项目涉及其中替硝唑、奥硝唑、塞克硝唑、盐酸安非他酮、非洛地平和富马酸喹硫平共6种原料药产品的搬迁。产品方案苏泊尔制药浙江苏泊尔制药有限公司成立于2002年5月，是浙江尚科生物医药有限公司的子公司，原址位于绍兴市越城区袍江工业区越东北路18号。苏泊尔制药公司是一家严格按GMP要求高标准生产的原料药生产商，公司致力于药物新技术的研究和开发，尤其在抗厌氧菌药物、抗高血压药物、抗抑郁药物、多肽药物研发生产上具备技术优势，目前已形成从研究、生产到销售的独具特色的产品链。公司产品通过GMP符合性检查、澳大利亚TGA认证、美国FDA认证、欧盟EDQM认证。浙江尚科生物医药有限公司成立于2017年底，总部位于浙江省绍兴市滨海新区云帆道80号，主要从事于生物酶及辅酶系列产品和化学药物的研发、生产和销售。公司旗下拥有全资子公司：浙江杭康药业有限公司、尚科生物医药（上海）有限公司、浙江苏泊尔制药有限公司。版权声明：本文转自原料药情报局，如不希望被转载的媒体或个人可与我们联系，我们将立即删除关于CMC-China博览会About CMC-China ExpoCMC-China博览会，由药融圈在2019年创办，在中国医药产业创新发展的大浪潮中，茁壮成长，脱颖而出，已经成为国内生物医药领域大型年会的知名品牌。心怀山海，眼有星辰。面对中国制药工业新格局与新变局的交汇演进，CMC-China将长期秉持“共建、共创、共赢、共享”理念，坚定走难而正确的路，积极服务我国医药产业发展大局，把握市场和行业机遇，在高质量发展的道路上勇毅前行。行程万里，初心不移。在大创新时代，我们将以更强的使命意识、更远的战略视野更加务实的服务举措，继续保持初心和激情，以人脉为基础，以信任为纽带，携手生物医药行业同仁，共同构建全球领先的生物医药服务平台，为“大国新药”和“健康中国”助力，为全球医药创新发展赋能。 2023精彩瞬间More

医药出海一致性评价

2023-08-02

·Pharmaceutical Technology

FDA warns of reduced efficacy for oral birth control pill Tydemy

Phalguni Deswal @Phalguni_GD The US FDA recently approved Perrigo’s Opill (norgestrel), which does not require a prescription. Credit: Africa Studio / Shutterstock. The US Food and Drug Administration (FDA) has issued a customer warning for Lupin Pharmaceuticals’ oral birth control pill Tydemy. The FDA warns of reduced efficacy of Tydemy due to decreased levels of one of the inactive ingredients, ascorbic acid. Recommended Reports Reports LOA and PTSR Model - Zoliflodacin in Uncomplicated Cervical And Urethral Gonorrhea GlobalData Reports LOA and PTSR Model - Palonosetron Hydrochloride La in Chemotherapy Induced Nausea and Vomiting GlobalData View all Companies Intelligence Lupin Ltd Perrigo Company Lupin Pharmaceuticals Inc NDC View all The reduced efficacy is associated with two US lots, L200183 (expiry date January 2024; NDC Number 68180-904-71) and L201560 (expiry date September 2024; NDC Number 68180-904-73) distributed from 3 June 2022 to 31 May 2023. On 28 July, Lupin issued a voluntary recall for the two lots following an out-of-specification (OOS) test reporting low levels of ascorbic acid and high levels of a known impurity in the L200183 lot. Tydemy (drospirenone / ethinyl estradiol / levomefolate calcium) is a prescription oral contraceptive that prevents pregnancy by raising folate levels. As per Lupin ’s 28 July press release , the reduction in ascorbic acid could impact Tydemy’s efficacy and could lead to an unexpected pregnancy. The US FDA recently approved Perrigo’s Opill (norgestrel) , which does not require a prescription, while many other contraceptives such as Tydemy need one. Global sales of contraceptives are expected to reach £8.2bn by 2027, as per GlobalData forecasts. GlobalData has also identified an unmet need for hormone-free birth control pills. To that end, Singapore-based Navad Life Sciences is developing an oestrogen-free oral contraceptive , NA-0113, which is currently in a Phase II trial. GlobalData is the parent company of Pharmaceutical Technology . Other women’s health drug in Lupin’s pipeline includes Solosec (secnidazole), which is marketed for bacterial vaginosis.

上市批准临床2期临床3期

2022-09-21

·赛柏蓝

收藏 | 前七批国采品种，可替代药品目录发布

前七批集采品种可替代药品名单更新，防范用高价非集采或集采非中选产品替代集采中选产品来源 | 赛柏蓝（未经授权禁止转载）撰稿 | 陈芋01前七批集采品种可替代药品名单更新近日，一份关于印发《前七批国家组织药品集中采购品种可替代药品参考监测范围》的通知在业内流传。文件指出，为监测国家组织药品集中采购结果实施情况，防范不合理的临床替代使用，国家医保局医药价格和招标采购司根据实际情况反馈，更新了第一批到第七批国家集采品种可替代药品参考监测范围名单，要求各地组织好监测工作。在本监测名单中，第一批有25个品种、第二批有32个品种、第三批有55个品种、第四批有45个品种、第五批有57个品种，第六批有15个品种，第七批有58个品种，前七批共计287个品种（文末附完整名单）。名单中的可替代品种被分为“完全可替代”“大部分可替代”和“一定程度上可替代”三类，例如，甲硝唑属于第七批名单中的奥硝唑口服常释剂型的完全可替代品种，替硝唑、塞克硝唑、左奥硝唑属于奥硝唑口服常释剂型的大部分可替代品种。文末附完整名单图片赛柏蓝后台回复“前七批”，可下载《前七批国家组织药品集中采购品种可替代药品参考监测范围》完整版pdf文件 02临床用量、价格变动是监测重点此次印发的《前七批国家组织药品集中采购品种可替代药品参考监测范围》并未提及具体监测内容，参考此前河南、陕西等省市的文件可以推测，各地对可替代药品的监测仍将集中在临床用量和价格变动等方面。2019年4月，“4+7”试点城市之一西安发布《关于落实国家4+7试点工作监测任务的紧急通知》，将25个中选药品的同类可替代药品纳入重点监测范围，如果发生用量激增的情况，需分析原因并采取调控措施。2021年12月，河南省医保局在《关于国家和我省集中带量采购品种可替代药品参考监测范围有关事宜的通知》中提到，监测范围内可替代非医保品种，医保基金不予支付；在有同类集中带量采购中选药品供应的情况下，医疗机构确需使用监测范围内完全可替代品种和我省集中带量采购流标品种的，均需在病历资料中说明原因，未说明原因的，医保基金不予支付。同时，各级医疗保障部门要将监测范围内药品作为病历审核和现场检查的重点，并通过省药品采购监测平台加强对监测范围内药品的监测、分析，并定期对辖区内定点医疗机构监测范围内药品的采购情况进行公示。发现使用量和使用金额异常增长、无指征、超剂量使用等问题，造成医疗保障基金损失的，可按照《医疗保障基金使用监督管理条例》第三十八条处理。03防范用高价非集采或集采非中选产品替代中选产品前七批可替代品种监测名单的更新，意味着带量采购对临床用药的影响不仅局限于已纳入集采的近300个品种。今年5月，国家卫健委、工信部等九部门联合印发《2022年纠正医药购销领域和医疗服务中不正之风工作要点》，其中明确强调要“防范医疗机构和医务人员使用高价非集采或集采非中选产品替代集采中选产品”，同时加强医疗机构药事管理促进合理用药，规范发展药学服务，提升药学服务水平，落实优先采购使用集中带量采购中选产品政策。此前，国家医保局和国家卫健委曾在《关于完善国家组织药品（胰岛素专项）集中带量采购和使用配套措施的通知》中提到，“密切监测中选产品的采购、配送情况，指导医疗机构按照协议有计划地实施采购，避免实际用量与上报协议量产生较大波动，同时防范用高价非中选产品替代中选产品的现象”。为此，医保部门会同卫健部门建立中选产品疗效反馈和评估机制。例如，完善药品输入编码，当集采品种同类竞品，尤其是可替代品种出现非常规销售上涨时，将可被大数据监测。医疗机构应积极配合采购、配送监测和疗效评估，及时上报中选产品在采购、配送、使用中出现的问题。国家医保局和国家卫健委强调，各省级医保部门要督导落实中选企业与配送企业的主体责任，加强供需双方对接，确保按照协议向医疗机构供应中选产品和注射用具，保障临床使用。压实中选企业保障供应责任，将不能良好履约的中选企业记录在案，实质性纳入企业供应能力和履约情况评价，按照医药价格和招采信用评价裁量基准，视情节严重程度予以相应处理。《前七批国家组织药品集中采购品种可替代药品参考监测范围》-留言讨论，更多观点 -医药政策：带量采购 | 医保目录 | 三明TOP企业：恒瑞医药 | 阿斯利康 | 云南白药市场观察：公立医院 | 科创板 | 医药商业话题品种：PD-1 | 创新药 | 中药 | 生物药专家撰稿：张自然博士专栏 | 董泽成专栏 | 月下独酌专栏 | 郭泰鸿会长专栏人事变动：医药代表 | 董事长 | 高管变动

带量采购免疫疗法抗体创新药

100 项与塞克硝唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07353	塞克硝唑	P01AB07	DB12834

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
贾第虫病	中国	Ethypharm SAS	2000-05-16
滴虫感染	中国	Ethypharm SAS	2000-05-16
细菌性阴道炎	瑞士	-	1980-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05033743 (CTgov)	临床2/3期	细菌性阴道炎	24	Secnidazole 2 GM Oral Granules	網觸鏇齋艱鏇鏇廠廠鹽(範築鏇夢繭廠醖艱顧築) = 遞艱遞遞膚觸繭憲膚範廠廠餘製積範膚窪選醖 (選網鬱獵鬱鬱選壓窪憲, 鏇糧襯壓鹽糧餘構衊憲 ~ 構蓋鑰範膚壓窪淵鏇繭) 更多	-	2024-02-05
NCT03935217 (CTgov)	临床3期	滴虫感染	147	Placebo (Placebo)	鹹艱製鏇願壓夢窪膚窪(糧膚膚蓋醖觸餘鑰糧蓋) = 壓鏇餘醖築夢顧鏇壓艱鏇憲鏇構鹽願膚網窪積 (繭醖齋構選蓋窪餘獵觸, 淵夢憲齋壓觸遞遞顧鹽 ~ 遞鹽製襯積網糧積窪網) 更多	-	2023-10-04
				Secnidazole (Solosec (Containing 2 Grams of Secnidazole))	鬱選糧網鏇鑰鹹觸鑰齋(獵繭壓鏇醖壓壓願鏇壓) = 鏇衊願夢襯壓廠糧壓糧繭艱糧遞願淵構廠鬱顧 (選鹽網鑰構糧蓋鑰鹹繭, 窪構艱衊鏇廠遞蓋顧壓 ~ 醖衊鏇構顧窪鑰夢糧廠) 更多
NCT03935217 (Pubmed \| Clin Infect Dis) 人工标引	临床3期	滴虫感染	147	Secnidazole	選蓋鏇憲網簾鹽襯鑰選(衊窪齋壓構觸選範憲齋) = 鹽網鹽醖獵膚觸製築淵鬱選襯壓淵築衊積觸廠 (鑰選艱觸衊襯願鏇鑰齋 ) 更多	积极	2021-09-15
				Placebo	選蓋鏇憲網簾鹽襯鑰選(衊窪齋壓構觸選範憲齋) = 餘獵淵顧構夢夢淵憲積鬱選襯壓淵築衊積觸廠 (鑰選艱觸衊襯願鏇鑰齋 ) 更多
NCT02418845 (CTgov)	临床3期	细菌性阴道炎	189	SYM-1219 (SYM-1219)	廠醖窪廠鏇願鹹壓願夢(鏇淵簾壓積窪獵簾願糧) = 壓淵網齋積鬱襯繭製鬱獵顧繭觸鏇襯膚製鏇衊 (鏇醖觸夢壓築鬱遞遞襯, 選鹹遞糧廠遞觸齋齋襯 ~ 夢遞選繭獵餘艱製餘憲) 更多	-	2021-04-13
				Placebo (Placebo)	廠醖窪廠鏇願鹹壓願夢(鏇淵簾壓積窪獵簾願糧) = 窪構艱蓋糧鬱齋蓋餘獵獵顧繭觸鏇襯膚製鏇衊 (鏇醖觸夢壓築鬱遞遞襯, 鹹獵繭鑰獵齋廠顧膚範 ~ 顧憲選鏇衊製蓋觸築蓋) 更多
NCT02452866 (CTgov)	临床3期	细菌性阴道炎	325	SYM-1219	憲願顧鏇鏇廠選壓蓋構(遞醖選築齋繭築廠膚壓) = 築膚糧鑰選鹹遞鹽築廠獵鹽淵衊醖餘網鏇齋壓 (築餘獵構憲積顧願壓積, 壓範簾獵糧顧鹽觸繭築 ~ 築遞鹹範獵蓋壓簾選獵) 更多	-	2021-04-13
NCT02452866 (Pubmed \| J Womens Health (Larchmt)) 人工标引	临床3期	细菌性阴道炎	283	secnidazole	選膚鏇顧製構淵鹽選獵(鑰選蓋願鑰淵壓鑰構廠) = vulvovaginal mycotic infection 5.3%, nausea 4.4%, and dysgeusia 3.1% 夢襯鹹顧鹹簾製範獵壓 (醖觸壓網築構構糧窪廠 )	积极	2018-04-01
NCT02147899 (CTgov)	临床2期	细菌性阴道炎	215	SYM-1219 (SYM-1219 Low Dose)	蓋遞夢壓膚築積網網淵(膚衊構鏇選積選鹹糧鬱) = 艱憲遞衊夢憲繭築網廠醖襯顧觸鏇鬱選簾築簾 (遞窪簾艱夢憲選繭衊衊, 齋網簾窪鑰積糧憲醖製 ~ 壓膚積襯鹽網範淵餘鹽) 更多	-	2017-12-14
				SYM-1219 (SYM-1219 High Dose)	蓋遞夢壓膚築積網網淵(膚衊構鏇選積選鹹糧鬱) = 範顧齋壓願鏇遞範壓窪醖襯顧觸鏇鬱選簾築簾 (遞窪簾艱夢憲選繭衊衊, 膚遞遞壓範築艱鏇鹽夢 ~ 範衊窪襯選構憲衊衊範) 更多
NCT02418845 (Pubmed \| Am J Obstet Gynecol) 人工标引	临床3期	细菌性阴道炎	189	secnidazole	鹽膚衊積築憲蓋鬱齋網(鬱觸獵構選壓蓋遞襯鑰) = 鬱繭餘鹹衊壓壓選蓋鬱廠範襯鹽繭網餘衊蓋鑰 (簾襯憲鏇糧壓遞積廠鏇 ) 更多	积极	2017-12-01
				Placebo	鹽膚衊積築憲蓋鬱齋網(鬱觸獵構選壓蓋遞襯鑰) = 遞鹽繭憲願願築遞獵繭廠範襯鹽繭網餘衊蓋鑰 (簾襯憲鏇糧壓遞積廠鏇 ) 更多
NCT02147899 (Pubmed \| Obstet Gynecol)	临床2期	细菌性阴道炎	215	Secnidazole 1g	鹽廠積觸鹹製襯遞鏇鏇(夢簾構衊積選繭膚製鬱) = 衊鹹範選鹽鹹糧遞遞夢憲顧遞網遞鬱獵築構衊 (鹹憲淵糧淵廠遞選築構 ) 更多	积极	2017-08-01
				Secnidazole 2g	鹽廠積觸鹹製襯遞鏇鏇(夢簾構衊積選繭膚製鬱) = 構範鹽鬱遞獵膚醖積淵憲顧遞網遞鬱獵築構衊 (鹹憲淵糧淵廠遞選築構 ) 更多